复合分配评分实施对肺再移植等待结果与移植后生存的影响
基于UNOS数据库2017年1月至2025年3月的21,569例成人肺移植患者,其中665例(3.1%)为再移植。再移植患者1年生存率显著低于首次移植(79.3% vs 89.2%,aHR 2.18,p<0.001)。
要点
- 再移植患者1年生存率显著低于首次移植(79.3% vs 89.2%,aHR 2.18)。
- 再移植患者三个时代的1年生存率无显著差异。
- CAS时代供体旅行距离和缺血时间更长,但等待结果无差异。
核心结论
- 再移植率、等待时间和1年生存率在不同时代间无变化,但CAS时代队列有限,不能得出等效性结论,需更大样本和更长随访研究。
研究设计与样本
- 回顾性队列研究,纳入UNOS数据库中2017年1月至2025年3月所有成人肺移植患者21,569例,其中再移植665例(3.1%)。
主要发现
- 再移植患者术前ECMO使用率(8.7% vs 3.6%,p<0.001)和呼吸机支持率(11.4% vs 2.7%,p<0.001)均高于首次移植。
- 再移植患者1年生存率显著低于首次移植(79.3% [75.9-82.3] vs 89.2% [88.7-89.6],aHR 2.18 [1.79-2.64],p<0.001)。
- 再移植患者三个时代的1年生存率无显著差异:Era 1为79.4% [73.4-84.2];Era 2为79.1% [73.5-83.7],aHR 0.96 [0.63-1.45],p=0.85;Era 3为80.1% [72.4-85.9],aHR 0.70 [0.42-1.17],p=0.18。
- 三个时代等待时间相似(p=0.28),等待期死亡率和移植率无差异(p>0.05)。
- Era 3再移植受者供体旅行距离和供体缺血时间均更长(均p<0.001)。
临床怎么用
- 再移植患者术前ECMO和呼吸机支持比例更高,应重视围术期风险评估。
- CAS实施后供体旅行距离和缺血时间延长,再移植中需关注供体获取效率。
局限性
- CAS时代队列有限,无法得出等效性结论。
- 需要更大样本和更长随访研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Lung Composite Allocation Score (CAS) was implemented in March 2023. While early evaluations showed no adverse effect of CAS on short-term survival for primary transplants, its impact on re-transplantation remains unknown. METHODS: We identified all adult patients from the United Network of Organ Sharing database who underwent lung transplantation between January 2017 and March 2025. The primary outcomes were one-year post-transplant survival compared between primary and re-transplant recipients and one-year post-transplant survival among re-transplant recipients compared across three eras: Era 1 (2017-2019), Era 2 (2020-March 9, 2023), and Era 3 (CAS, March 9, 2023-March 2025). RESULTS: Among 21,569 patients, 665 (3.1%) underwent re-transplantation. Compared to primary transplants, re-transplant recipients required more pre-operative ECMO (8.7% vs 3.6%, p<0.001) and more ventilator support (11.4% vs 2.7%, p<0.001). Re-transplants had significantly worse 1-year survival (79.3% [75.9-82.3] vs 89.2% [88.7-89.6], aHR 2.18 [1.79-2.64], p<0.001). Among re-transplants, there were no differences in 1-year survival across eras (Era 1: 79.4% [73.4-84.2]; Era 2: 79.1% [73.5-83.7], aHR 0.96 [0.63-1.45], p=0.85; Era 3: 80.1% [72.4-85.9], aHR 0.70 [0.42-1.17], p=0.18). The waitlist times across eras were similar (p=0.28). However, Era 3 recipients had longer donor travel distances and longer donor ischemic times (both p<0.001). There were no differences in waitlist mortality or transplant rates for re-transplants between eras (p>0.05). CONCLUSIONS: Re-transplant rates, waitlist times, and one-year survival were unchanged across eras. However, the limited CAS-era cohort precludes conclusions regarding equivalence, and larger studies with longer follow-up are needed.
引用
- Krishna V, Razavi AA, Lim B, et al. The Impact of Composite Allocation Score Implementation on Waitlist Outcomes and Post-Transplant Survival in Lung Re-Transplantation. Ann Thorac Surg. 2026. PMID: 42849596. doi:10.1016/j.athoracsur.2026.09.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。